Nachrichten zur Esperion Therapeutics Aktie

Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference

ANN ARBOR, Mich., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that president and chief executive officer, Tim…

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on January 2,…

Esperion (ESPR) Almost Doubled In 2019, What Awaits The Stock In 2020-

Shares of Esperion Therapeutics Inc. (ESPR), which closed at a new 52-week high of $61.34, have gained more than 60%…

Esperion Therapeutics (ESPR) Up 25.1% Since Last Earnings Report: Can It Continue-

Esperion Therapeutics (ESPR) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Esperions Promising Drugs Under Review, Funds a Concern

Esperions (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, absence…

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 20,…

Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10%

Esperion Therapeutics (ESPR) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge…

Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions

ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from…

Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3

Esperion Therapeutics (ESPR) reports mixed third-quarter results....…

Esperion Therapeutics EPS misses by $0.57, misses on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Therapeutics: Low Risk And Primed For Substantial Growth

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound-

Esperion Therapeutics (ESPR) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Esperions bempedoic acid successful in mid-stage study in type 2 diabetics with high cholesterol

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion combo pill successful in mid-stage study in type 2 diabetics with high cholesterol

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion: Establishing A Position Ahead Of The PDUFA Date

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperions Drugs in Review Hold Potential, Funds a Concern

Esperions (ESPR) regulatory applications for bempedoic acid monotherapy and combo therapy seeking approval for lowering LDL-C are under review. However,…

Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat

Esperion Therapeutics (ESPR) reports mixed second-quarter results....…

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -8.06% and 5.25%, respectively, for the quarter ended June 2019. Do…

Top Analyst Upgrades and Downgrades: Allstate, CalAmp, Chubb, Costco, Esperion, Flex, Hartford, Nio, Rockwell Automation, Roku and More

Um den gesamten Artikel unter feedproxy.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Is The One To Watch, After FDA Deems Advisory Panel Is Not Needed

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Heres Why Esperion Therapeutics Shares Rocketed 11.5% Higher Today

The company is one step closer to securing an OK for its new cholesterol-busting drug....…

Small-Cap Biotech Esperion Surges On FDA Acceptance Of Cholesterol Drug Applications

Shares of small-cap biotech Esperion Therapeutics Inc (NASDAQ: ESPR) were rallying Monday after the company received good news from the…

Esperion Therapeutics wins FDA approval on a pair of new drug applications; shares jump

Esperion Therapeutics Inc (NASDAQ:ESPR) said it has earned the Food and Drug Administrations approval on two new drug applications, sending…

Esperion Therapeutics: Investment Case

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion unveils positive human trial results for new cholesterol-lowering drug

Esperion said that bempedoic acid is under development as a complementary, cost-effective, once-daily and oral therapy to treat patients with…

Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4

Esperion Therapeutics (ESPR) generates no revenues in the fourth quarter. The company provides guidance for 2019....…

Esperion Therapeutics: Buy, Sell Or Hold-

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

For Esperion Therapeutics, 2019 Could Be a Big Year

The developer of a new cholesterol-lowering treatment is on a path toward commercialization....…

Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today

Even in a surging market, these stocks fell. Find out why....…

Esperion to receive $300 million in upfront payments in deal with Daiichi Sankyo

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Do Options Traders Know Something About Esperion (ESPR) Stock We Dont-

Investors need to pay close attention to Esperion (ESPR) stock based on the movements in the options market lately....…

Whats Next for Esperion Therapeutics Cholesterol-Lowering Drug

The companys making big strides toward winning approval of its first commercial medicine....…

Esperion CEO on safety of new cholesterol drug

CNBC's Meg Tirrell reports on Esperion shares heading higher on its new cholesterol drug. Esperion CEO and President Tim Mayleben…

Esperion Therapeutics shares pop on successful Phase 3 trial for bempedoic acid

Esperion Therapeutics (NASDAQ:ESPR) is picking up traction Monday in the wake of its announcement of optimistic results from its Phase…

Esperion stock surges 15% on late-stage results for cholesterol drug

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperions cholesterol drug bempedoic acid succeeds in phase 3 trial

The 52-week, randomized, double-blind, placebo-controlled study investigated the LDL-C lowering efficacy and the safety and tolerability of bempedoic acid 180mg…

ESPR To Submit NDAs In Q1, GRFS Alzheimers Study Brings Hope, RTRX On Watch

Todays Daily Dose brings you news about Anavexs encouraging results from its Alzheimers study; Esperions promising phase III clinical development…

Do Options Traders Know Something About Esperion (ESPR) Stock We Dont-

Investors need to pay close attention to Esperion (ESPR) stock based on the movements in the options market lately....…

Esperion Therapeutics: Hold For PDUFA Date

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Are Options Traders Betting on a Big Move in Esperion (ESPR) Stock-

Investors need to pay close attention to Esperion (ESPR) stock based on the movements in the options market lately....…

Esperion: Strong Data To Capture The High Cholesterol Market

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Therapeutics (ESPR) Bempedoic Acid / Ezetimibe Combo Pill and Bempedoic Development Program - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion (ESPR) Combination Regimen Lowers Bad Cholesterol

Esperion Therapeutics (ESPR) combination regimen of bempedoic acid and Mercks Zetia achieves significant reduction in bad cholesterol in a phase…

AFMD Soars On Genentech Deal, AKCA Slumps On Rejection, FDA Nod For TTPH

Todays Daily Dose brings you news about the Complete Response Letter issued for Akcea; FDA approval of Tetrphase Pharmas XERAVA;…

UPDATE 1- Esperions combo therapy lowers cholesterol level by 35 pct, shares surge

Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Mercks Zetia lowered cholesterol level by…

0ET: WIEDERAUFNAHME/RESUMPTION

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

Esperion says combo therapy lowers cholesterol level by 35 pct

Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Mercks Zetia lowered cholesterol level by…

Esperion announces positive results in trial of cardiovascular treatment

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

0ET: AUSSETZUNG/SUSPENSION

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

Esperion: Elucidating The Upcoming Clinical Binaries

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…